Chinese consumers, once the engine of growth for multinational companies, are cutting back on all kinds of things. Designer ...

TD Cowen had upgraded Merck in early 2024 based on confidence in Keytruda and Gardasil’s performance, a lack of binary risks, and an attractive valuation. However, setbacks in Gardasil’s China ...

They're all talking about HPV, or human papillomavirus. It's the most common sexually transmitted infection, but it's also ...

We recently published a list of 10 Important News Updates Investors Shouldn’t Miss. In this article, we are going to take a ...

TD Cowen had upgraded Merck in early 2024 based on confidence in Keytruda and Gardasil’s performance, a lack of binary risks, and an attractive valuation. However, setbacks in Gardasil’s China sales ...

Shares of Merck & Co. Inc. fell more than 0.5% on Monday afternoon, tracking their fifth consecutive decline in the worst ...

Bernstein SocGen Group has revised its price target for Merck (NYSE:MRK) shares, bringing it down to $95 from the previous $110 while maintaining a Market Perform rating. Analyst Courtney Breen cited ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

Investing.com -- TD Cowen downgraded Merck & Company Inc (NYSE:MRK) to "Hold" on concerns over uncertainty surrounding Gardasil sales, a slowdown in business development, and the looming loss of ...

Gardasil vaccine protects against cancer-causing human papilloma virus or HPV infections. The pause announcement comes a month after Merck received approval in China for use of the vaccine in males.

The HPV vaccine has the most misinformation of any ... Ongoing lawsuits allege Merck didn’t fully disclose severe and long-term side effects. A condition plaintiffs allege they received from ...